Share Name Share Symbol Market Type Share ISIN Share Description
Tissue Regenix LSE:TRX London Ordinary Share GB00B5SGVL29 ORD 0.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25p -3.12% 7.75p 7.50p 8.00p 8.00p 7.75p 8.00p 140,897 14:39:04
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.4 -10.9 -1.3 - 90.80

Tissue Regenix (TRX) Latest News

More Tissue Regenix News
Tissue Regenix Takeover Rumours

Tissue Regenix (TRX) Share Charts

1 Year Tissue Regenix Chart

1 Year Tissue Regenix Chart

1 Month Tissue Regenix Chart

1 Month Tissue Regenix Chart

Intraday Tissue Regenix Chart

Intraday Tissue Regenix Chart

Tissue Regenix (TRX) Discussions and Chat

Tissue Regenix Forums and Chat

Date Time Title Posts
26/1/201808:37Tissue Regenix delivering practical solutions to real clinical issues2,054
24/5/201609:30Third time lucky6,918
29/6/201320:26TOREX 2007 - THE TILLS RING AT LAST8
24/3/201312:45Torex - an insiders tale23
24/9/201209:10Torex Retailing8

Add a New Thread

Tissue Regenix (TRX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-02-20 15:38:577.50133,69710,027.28O
2018-02-20 14:25:547.5520015.10O
2018-02-20 11:39:347.557,000528.50O
View all Tissue Regenix trades in real-time

Tissue Regenix (TRX) Top Chat Posts

Tissue Regenix Daily Update: Tissue Regenix is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker TRX. The last closing price for Tissue Regenix was 8p.
Tissue Regenix has a 4 week average price of 7.75p and a 12 week average price of 5.63p.
The 1 year high share price is 19.50p while the 1 year low share price is currently 5.63p.
There are currently 1,171,649,005 shares in issue and the average daily traded volume is 71,292 shares. The market capitalisation of Tissue Regenix is £90,802,797.89.
channel pirate: Well the company are good at manufacturing tissue to repair / heal wounds etc, so maybe they ought to manufacture a positive RNS that will repair the share price which has been severely wounded over the past few months !!
andrewbaker: Adding to and following on from post 1934 in June, it's heartening to know that even a business that's not blessed with the best management, can become compelling when the product is really good and the share price way too low. What we really need is better figures, and better management; then this can really go. I'd buy more, but I'm already loaded to the gills, and can't destabilise my portfolio by doing so: so ... you guys drink your fill, and enjoy what should be, better late that never, a big rise northwards (and more northwards than before, too). ... Couldn't resist it: bought another 15,000 at 13.95p. I'm holding a heck of a lot more, so ok for this top-up, IMHO. lol. :)
channel pirate: With the share price having lost just over 35.36% in the last 6 months, then we could do with some good supporting news right now, or like "yesterday" and not "tomorrow". I have built a nice size holding during these past 6 months, but will not be panic selling or adding more until we get some positive news from the company.
channel pirate: Morning bamboo2, Guessing, then the new Holdings Company has been inaugurated to acquire acquisitions the Main Company has in their sights as being beneficial to the Main Company – hence the recent RNS regarding CellRight Technologies, LLC ("CellRight"). To me then this indicates the Company is getting “stronger̶1; all round and is expanding, generating more income etc, both of which has not yet been updated to the market. I would expect the large shareholders (Invesco, Woodford etc) are already briefed what is happening, especially with the share price languishing at the present low price, which must have knocked millions off the value of their holdings. I’m looking forward to the Prelims, and let’s hope it reassures us small pi’s also that we have “boarded the right train”.
channel pirate: Thought I would send an email to Investor Relations at the company this morning - will post the reply should I get one............. Good morning Caitlin, Being a shareholder with a six figure holding it is sad to see some shareholders exiting due to a falling share price and a lack of updates from the company. This time last year the company had already announced via the market of when it was going to report it’s Accounts & Report for the preceding year. Can you advise me of when we are likely to hear from the company in respect of progress and the last financial years Accounts. Thanking you in anticipation. Kind Regards,
channel pirate: Share Price at beginning of the year was 20.5p, and tonight it has fallen to 15.5p, so a 24.39% drop in 3 months. Let's hope we are not going to test the next fib level 'down' !!
channel pirate: Just been looking back through some of the company announcements over the last few months which re-assures me of my holding and maybe that on this dip, or subsequent dips, then it might be prudent to start adding again. From the announcement on 28th November : “The launch of OrthoPure™ XT remains on track for H1 2017, with CE mark approval in the same period. The first distribution agreements within Europe have been signed, indicators of the strong commercial and clinical support for OrthoPure™ XT, in preparation for rapid commercialisation in key European markets once approval is granted. Peter Hamer, Commercial Director TRX Orthopaedics Ltd: "We are extremely encouraged by the initial results returned from the study. Having entered our first distributor agreements, which highlight the demand and market opportunity for OrthoPure™ XT, we remain on track for launch of OrthoPure™ XT by the end of H1 2017.” So anytime in the next 4 months if all goes to plan, and that should see a significant rise in the share price if we are lucky ??
multibagger: Hi Swiss Paul, Some very valid and searching questions. The biotech/healthcare product market is a very complex one due to various procurement and payment schemes/methods. In the UK, the NHS is a slow adopter and constrained by cost.The US is a much higher cost healthcare system and if TRX finds traction there, then there will be an uplift in share price. Though I keep an eye on TRX, I am not of the view that the share price will move upwards fast and not invested currently. I'm not a fan of either Odell or Samuels having met them both in Leeds at the AGM a few years ago, when I was the only shareholder present ! I'm not convinced about their their tech pipeline either, as regenerative medicine is moving a lot quicker than TRX are. I sold out not long after. My approach to biotech investing has changed and now largely go for funds....I hold AXA Framlington Biotech though I made good money from SCLP, SUMM and SAR in the past.Cyprotex (CRX) is moving in the right direction and their R&D product delivery and commercialisation is much more attractive - I pointed it out here when it was about 60p on this board - now about 135p. I hope TRX comes good for all holders - but my take is that investors may have a fairly long wait. Good luck all :)
bamboo2: Could be interim results from Meniscus trial as soon as next week. =========================================== 30 June 2016 Tissue Regenix Group plc Deferred Annual Bonus Scheme Leeds, 30 June 2016 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Company") the regenerative medical devices company announces that an award has been made to Ian Jefferson, Chief Financial Officer and Antony Odell, Chief Executive Officer, pursuant to the terms of the Company's Deferred Annual Bonus Scheme. Under the terms of the Deferred Annual Bonus Scheme, Ian Jefferson waived his entitlement to receive 50% of his annual cash bonus in return for an option over 209,677 ordinary shares of 0.5p each in the Company and Antony Odell waived his entitlement to receive 36% of his annual cash bonus in return for an option over 255,484 ordinary shares of 0.5p each in the Company (the "Deferred Allocation"). The number of shares comprising the Deferred Allocation (i.e. subject to option) was calculated by dividing the amount of cash bonus waived by the closing market value of the ordinary shares of the Company on the dealing day immediately prior to the date of deferral. The Deferred Allocation option is not capable of exercise until the vesting date has been reached, which is three years from the date of the award. By participating in the Deferred Annual Bonus Scheme Ian Jefferson and Antony Odell are entitled to receive a matching award at no additional cost (the "Matching Allocation"), being an option over 629,031 and 766,452 ordinary 0.5p shares in the Company respectively. The Matching Allocation is not capable of exercise until the vesting date has been reached, which is three years from the date of award. Additionally, the Matching Allocation is not capable of exercise until the Company's share price has reached the following target prices and remained at those prices for at least 30 consecutive days: Performance criteria % Of Interest .Share Price To Vest ..........Criteria -------------- ------------ 33.33% .........20p -------------- ------------ 33.33%......... 25p -------------- ------------ 33.33%......... 30p -------------- ------------
multibagger: Hi discussion and points of view are largely seems to be supportive of an upward trending TRX share price and I am certainly not complaining :) The market is what matters and decides the share price, not my opinion !
Tissue Regenix share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20180221 05:44:28